Na tu'uina atu e Halia Therapeutics fa'amaumauga i aso nei i lana polokalame fa'atosina NLRP3 i le aso 10th Neurodegenerative Drug Development Summit i aso nei.

O Dr. David J. Bearss, Peresetene, ma le Pule Sili o Halia Therapeutics, na faʻaalia ai faʻamatalaga e faʻaalia ai le faʻaogaina o le faʻaogaina o le allosteric faʻatatau i se vaega o le NLRP3 faʻalavelave na mafai ai ona mamanuina se vasega fou o mea faʻapipiʻi e taulaʻi uma le NLRP3 faʻagaioiga ma galuega. O nei vaila'au mole laiti e mafai ona fa'atatau i le tele o fa'ailoga fa'ama'i fa'ama'i ma neura. O le folasaga a Dr. Bearss sa fa'aulutalaina, “Target the NLRP3 Inflammasome for the Treatment of Alzheimer's Disease.” Na faia le Summit i Boston Park Plaza, Boston, Massachusetts, mai ia Mati 28 e oo i le 30, 2022.

“O fa'amaumauga ma fuafuaga o lo'o tu'uina atu i aso nei o lo'o fa'atusalia ai se fa'ata'ita'iga fou mo le fa'atatauina o le NLRP3. Matou te matua fiafia lava e uiga i le mauaina o mea faʻapipiʻi allosteric o le NLRP3 inflammasome, ma o loʻo matou alualu i luma le tele o polokalame agai i le falemaʻi e faʻaaoga ai lenei fuafuaga faʻatatau, "o le tala lea a Jared Bearss, COO a Halia. "O le malosi e faʻalavelave uma ai le faʻapotopotoga ma faʻalauiloaina le faʻamavaeina o le NLRP3 inflammasome complex e fai ma sui o se avanoa taua e tuʻuina atu ai togafitiga fou mo tagata mamaʻi o loʻo mafatia i faʻamaʻi faʻamaʻi ma faʻamaʻi."

OA MEA E AVEA MAI LENEI TUSI:

Bearss, President, and CEO of Halia Therapeutics, highlighted results demonstrating how using an allosteric targeting approach to a component of the NLRP3 complex enabled the design of a new class of compounds that target both NLRP3 activation and function.
“The ability to both inhibit the assembly and promote the disassembly of the NLRP3 inflammasome complex represents a significant opportunity to provide new therapeutics for patients suffering from neurological and inflammatory diseases.
We are very excited about discovering allosteric modulators of the NLRP3 inflammasome, and we are progressing multiple programs toward the clinic using this targeting strategy,”.